Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced that William Rote, Ph.D., the Company’s chief research officer, plans to retire from the Company in February 2027 following 10 years of ...
Is TVTX a good stock to buy? We came across a bullish thesis on Travere Therapeutics, Inc. on Biotech Distilled’s Substack.
AZN's Ultomiris wins FDA priority review for IgAN, backed by late-stage data showing a 43.4% proteinuria reduction versus ...
Wells Fargo analyst Mohit Bansal maintained a Buy rating on Travere Therapeutics yesterday and set a price target of $65.00. Designed for personal research, portfolio monitoring, and AI-assisted ...
EVEREST MED (01952.HK) announced that its wholly owned subsidiary, Everest Medicines (Singapore) Pte. Ltd., as licensor, has ...
Today’s analyst ratings show a mixed but still broadly constructive market tone, with increasing dispersion in conviction. Analysts continue to support lon ...
Investor's Business Daily on MSN
Stock market today: Dow ends higher on Iran deal hopes; SpaceX rockets 19% in debut
Stock Market Today: The Dow Jones index rises Friday on U.S.-Iran peace deal hopes. SpaceX stock jumps on its debut.
Fresh off a deal with Travere Therapeutics Inc. for civorebrutinib worth more than $1.14 billion, Everest Medicines Ltd. went on a shopping spree, striking three deals in six days to expand its ...
Compare risk profiles, sector concentration, and income potential as these two healthcare ETFs take different approaches to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results